Product Information
DORZOLAMIDE-TIMOLOL EYE DROPS is a generic product labeled by Sandoz Inc., priced at $0.8927 per ML under NDC 61314003002. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Nov 18, 2009. Its Orange Book therapeutic-equivalence code is AT1.
Strength
20; 5 mg/mL; mg/mL
Manufacturer
Sandoz Inc.NDC
61314003002
Classification
Generic
Dosage Form
SOLUTION
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATEApproval Type
Generic (ANDA)
FDA Application
ANDA090604FDA Approved
11/18/2009
TE Code
AT1
On Market Since
1/2/2010
Pharmacological Classes
Price Statistics
The NADAC for DORZOLAMIDE-TIMOLOL EYE DROPS has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 41.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8927 per ML |
|---|---|
| All-time high | $1.8342 (Jul 15, 2020) |
| All-time low | $0.8203 (Dec 20, 2017) |
| 52-week high | $1.0228 |
| 52-week low | $0.8853 |
| Median price | $1.1818 |
| Average price | $1.2397 |
| Largest weekly change | +19.7% (Feb 20, 2019) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Dorzolamide Hydrochloride and Timolol Maleate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sandoz Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Dorzolamide Hydrochloride and Timolol Maleate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Carbonic Anhydrase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DORZOLAMIDE-TIMOLOL EYE DROPS?
The current National Average Drug Acquisition Cost (NADAC) for DORZOLAMIDE-TIMOLOL EYE DROPS, manufactured by Sandoz Inc., is $0.8927 per ML (NDC 61314003002), effective Sep 30, 2026.
How has the price of DORZOLAMIDE-TIMOLOL EYE DROPS changed over time?
Over the history we have for it, the NADAC for DORZOLAMIDE-TIMOLOL EYE DROPS has declined 41.0%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for DORZOLAMIDE-TIMOLOL EYE DROPS?
Since Nov 28, 2013, the NADAC for DORZOLAMIDE-TIMOLOL EYE DROPS has ranged from a low of $0.8203 (Dec 20, 2017) to a high of $1.8342 (Jul 15, 2020), with a median of $1.1818 per ML.
Are there cheaper alternatives to DORZOLAMIDE-TIMOLOL EYE DROPS?
No other NADAC-published product currently shares the active ingredient and strength of DORZOLAMIDE-TIMOLOL EYE DROPS in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DORZOLAMIDE-TIMOLOL EYE DROPS?
DORZOLAMIDE-TIMOLOL EYE DROPS (NDC 61314003002) is labeled by Sandoz Inc., and CMS classifies it as a generic product.